2017
Peritoneal B-1b and B-2 B-cells confer long-term protection from pneumococcal serotype 3 infection after vaccination with Prevnar-13 and are defective in sickle cell disease mice
Cotte C, Szczepanek S. Peritoneal B-1b and B-2 B-cells confer long-term protection from pneumococcal serotype 3 infection after vaccination with Prevnar-13 and are defective in sickle cell disease mice. Vaccine 2017, 35: 3520-3522. PMID: 28545925, DOI: 10.1016/j.vaccine.2017.05.039.Peer-Reviewed Original ResearchConceptsLong-term immunitySickle cell disease micePrevnar-13SCD miceDisease miceRecipient miceB cellsPneumococcal conjugate vaccineMice three timesB cell subsetsWild-type miceB-1aB-1a cellsSerotype 3 infectionB-1bConjugate vaccineWT miceLong-term protectionStreptococcus pneumoniaeSubset functionsMiceVaccinationWeek intervalsImmunityThree times
2016
Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers
Szczepanek S, Roberts S, Rogers K, Cotte C, Adami A, Bracken S, Salmon S, Secor E, Thrall R, Andemariam B, Metzger D. Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers. PLOS ONE 2016, 11: e0149261. PMID: 26910228, PMCID: PMC4766082, DOI: 10.1371/journal.pone.0149261.Peer-Reviewed Original ResearchConceptsSickle cell diseaseAnti-pneumococcal antibody titerSCD miceAntibody titersPrevnar-13Pneumococcal vaccinationPneumococcal infectionControl miceSickle cell disease miceIntranasal pneumococcal infectionPoor long-term efficacyLong-term efficacyMouse challenge modelPolysaccharide conjugate vaccinesInitial IgGPneumococcal vaccineIntranasal infectionIgM responseAntibody responseDisease miceImmune protectionPneumococcal polysaccharideSCD groupCell diseaseCommon cause